| Literature DB >> 14560689 |
E J Duiverman1, H J Brackel, P J Merkus, B L Rottier, P L Brand.
Abstract
The second revision of the guidelines for the treatment of asthma in children is largely based on the evidence of comparative studies. Short-acting beta 2-sympathicomimetics are the medication of choice for acute exacerbations and should therefore be prescribed to each patient. Inhaled corticosteroids (ICS) are the medication of choice for maintenance treatment. Starting with a high dose of ICS which is then reduced to a lower but effective level on the basis of the complaints (step-down approach) is no longer recommended, as this strategy is not more effective than a constant dosage schedule. If asthmatic symptoms persist despite ICS maintenance treatment then 3 therapeutic options are available in the following order: doubling the ICS dose, the addition of a long-acting beta 2-sympathicomimetic, and the addition of a leukotriene receptor antagonist.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14560689
Source DB: PubMed Journal: Ned Tijdschr Geneeskd ISSN: 0028-2162